einstein (São Paulo). 31/Jan/2014;11(4):492-4.
Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital
DOI: 10.1590/S1679-45082013000400015
OBJECTIVE: To compare the efficacy and the period of use of tocilizumab and infliximab during treatment of rheumatoid arthritis patients. METHODS: The period of use of two biologics with different mechanisms of action were compared in treatment of rheumatoid arthritis patients. RES: ULTS: Both medications showed efficacy, but the period of use with no loss of efficacy was longer in patients receiving tocilizumab when compared to infliximab. CONCLUSION: Tocilizumab maintains a period of use significantly longer as compared with infliximab in patients with rheumatoid arthritis treated at a single organization.
Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital
291